Replies to post #474 on Endra Life Sciences Inc (NDRA)

[dndodd]

I know you didn’t ask me but thought I would add my .02.

I don’t think the Market really knows about TAEUS yet that will come with sales and FDA approvals.

The warrants exercised at .70 but they paid approximately.14 for each warrant for a total cost .84 to the investor.

The insiders exercised their warrants a couple of weeks earlier at full price of .87 plus the .14 they paid. Bullish IMO.

[Sluicebox]

I think very few knows about Endra.
The point many misses is that gold standard is achieved by a very expensive MRI scanning, and is really not part of standard of care in the early lines of NAFLD, which is where the big market opportunity is for Endra. To diagnose and start treatment of NAFLD in the early stage.

I think the implementation of TAEUS, based on current data, is to replace biopsy, fribroscan and ultrasound at specialist after their Primary Care Physician has established suspicion of NAFLD.

Fact that current major share holders want to buy more shares is great. They paid about .84. Had it been a public offering they would have had to give 15-20% discount on sp anyway, so we might be better of this way.

Endra looks very promising, but they need to publish more data and should test in combination with standard non invasive markers, such as blood tests, BMI ect ect, as these are done anyway at the PCP.
All adds up to a better Sensitivity / specificity.